Redefining digestive health by pioneering non-endoscopic diagnostics, enabling early detection of diseases and access to care for everyone, everywhere.
Cambridge, England
Joined June 2020
- Tweets471
- Following347
- Followers523
- Likes771
Pinned Tweet
Our EndoSign® cell collection device has received 510(k) clearance from the FDA, enabling earlier and more efficient detection of esophageal pre-cancer and other conditions.
#DetectToProtect #FDA
Consultant Upper GI Surgeon Craig Vickery shared how @WestSuffolkNHS integrated EndoSign® into its #reflux pathway, reducing wait times for an appointment.
Read more: content.yudu.com/web/1u0jl/0…
#EndoSign
EndoSign® is not designed to replace endoscopy.
It's designed to help identify which patients are most likely to benefit from it, supporting more targeted referrals and helping protect endoscopy capacity.
endosign.com/
#Endoscopy #EndoSign
Persistent #reflux shouldn't be ignored.
@HeartburnCancer UK's blog highlights Jess’s Rule, encouraging GPs to review patients presenting three times with the same symptoms. Earlier investigation can make a difference:
Discover EndoSign® for #heartburn: heartburncanceruk.org/blog/w…
Cyted Health retweeted
💣 Big data drop at #ACG2026! @CytedHealth’s #BarrettsEsophagus test delivers 90% sensitivity and 86% specificity 💥
🗨️ Hope on the horizon for 9️⃣0️⃣% of undiagnosed BE patients in the U.S., says Dr. Marcel Gehrung vist.ly/5ne67
Cyted Health retweeted
@CytedHealth’s EndoSign detects Barrett’s esophagus with 90% sensitivity in US study pharmadevicenews.com/cyted-h… EndoSign achieved 90% sensitivity and 86% specificity for Barrett's esophagus in a prospective 324-participant US study, with successful cell collection in 95% of patients. Cyted Health also reported 100% sensitivity for dysplasia and esophageal cancer, but positive results still require endoscopy and the molecular test itself is not FDA-cleared. #CytedHealth #EndoSign #DETECTME #BarrettsEsophagus #EsophagealCancer #MolecularDiagnostics #EarlyDetection #MedicalDevices #Gastroenterology #ACG2026
Changes to #FIT criteria are expected to increase NHS #endoscopy activity by 35 %. With services already under pressure, effective triage is more important than ever.
Read how EndoSign® can help protect capacity: endosign.com/post/how-can-en…
We’re pleased to welcome Thomas A. West as Board Chair and Epstein, Robert as Non-Executive Director at Cyted.
Their combined expertise will be invaluable as we continue to bring earlier, more accurate detection of esophageal disease to more patients.
cytedhealth.com/uk/post/cyte…
What support is available to help teams deliver EndoSign® in the NHS?
We provide training and ongoing support, with a cascade training model to help build sustainable local expertise.
Learn more: endosign.com/hcp/endosign-in…
#EndoSign #Gastroenterology #NHS
20 % of the UK population experiences GORD, yet serious pathology is rare.
How can services identify high-risk patients without overwhelming endoscopy pathways?
Read our article that explores risk stratification with EndoSign®: gastroenterologytoday.com/vi…
#GORD #EndoSign
Many #NHS services are moving beyond endoscopy-first approaches with risk stratification, nurse-led assessment and less invasive investigations with EndoSign®.
How has your pathway evolved? endosign.com/
How do patients respond to EndoSign?
A study with EndoSign® reported a 95.3 % swallow success rate and no adverse complications.
Read the study from @gastroendonews : gastroendonews.com/PRN/Artic…
Eddie lived with heartburn for 40+ years, unaware it could lead to cancer.
One capsule sponge test detected early cell changes, leading to treatment before the disease could progress.
Read his story: youtube.com/watch?v=4ICuevA9…
#Reflux #EndoSign #OesophagealCancer
Not every Barrett's oesophagus patient carries the same cancer risk. So, should everyone follow the same surveillance pathway?
Read our article in @thenhenews that discusses how biomarker-based risk stratification can support more targeted care: nationalhealthexecutive.com/…
A UK study found sponge-based surveillance detected more high-grade dysplasia or adenocarcinoma than endoscopy.
A second study with EndoSign® reported a 95.3 % swallow success rate and no adverse complications.
Read more in @gastroendonews:
gastroendonews.com/PRN/Artic…
Clinicians are being urged to reduce low yield endoscopies, and earlier risk stratification could be key to this.
EndoSign® capsule sponge testing offers minimally invasive triage to support targeted referral.
Learn more: endosign.com
#Endoscopy #BarrettsOesophagus
What is the difference between capsule endoscopy and capsule sponge technology?
Explore more of our frequently asked questions:
#UpperGI #Diagnostics #OesophagealCancer #Reflux #Endoscopy
31-MarYou may know EndoSign® as the ‘pill on a string’ – but what is it?
A minimally invasive triage tool that collects oesophageal cells to assess #reflux and Barrett’s risk.
Learn more: endosign.com
#OesophagealCancer #Reflux
Oesophageal cancer is often diagnosed late, impacting outcomes. 5 year survival can be ~95 % when detected early, but reduces to 5-40 % at advanced stages.
EndoSign® enables minimally invasive risk stratification for targeted referrals.
Learn more: endosign.com
Up to 75 % of UK #gastroscopies may be performed in patients with <1 % cancer risk.
Earlier risk stratification could reduce low yield procedures. EndoSign® supports minimally invasive assessment to better target #endoscopy.
Learn more: endosign.com
What do patients think of EndoSign® capsule sponge test?
Read more about the patient experience here:
#HeartburnHealthCheck #OesophagealCancer #EarlyDiagnosis #NHSInnovation
